A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis

British Journal of Dermatology

Volumn 173, Issue 3, 2015, Pages 681-689

  Takahashi, T ^a   Asano, Y ^a   Noda, S ^a   Aozasa, N ^a   Akamata, K ^a   Taniguchi, T ^a   Ichimura, Y ^a   Toyama, T ^a   Sumida, H ^a   Kuwano, Y ^a   Tada, Y ^a   Sugaya, M ^a   Kadono, T ^a   Sato, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSCRIPTION FACTOR FLI 1; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; ANIMAL; APOPTOSIS; CASE CONTROL STUDY; FIBROSIS; LUNG DISEASES; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; SCLERODERMA, SYSTEMIC; SKIN; SKIN DISEASES, VASCULAR; VASCULAR DISEASES;

ACUTE-PHASE PROTEINS; ADULT; AGED; ANIMALS; APOPTOSIS; CASE-CONTROL STUDIES; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; HUMANS; LIPOCALINS; LUNG DISEASES; MALE; MICE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RENAL INSUFFICIENCY, CHRONIC; SCLERODERMA, SYSTEMIC; SKIN; SKIN DISEASES, VASCULAR; VASCULAR DISEASES;

EID: 84942364449     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13779     Document Type: Article

References (53)

1. Asano Y,. Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
2. Masui Y, Asano Y, Shibata S, et al., Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 2012; 26: 354-60.
3. Masui Y, Asano Y, Takahashi T, et al., Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. Mod Rheumatol 2013; 23: 323-9.
4. Masui Y, Asano Y, Shibata S, et al., A possible contribution of visfatin to t he resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response. Rheumatology (Oxford) 2013; 52: 1239-44.
5. Masui Y, Asano Y, Akamata K, et al., Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis. Rheumatol Int 2014; 34: 1165-70.
6. Toyama T, Asano Y, Takahashi T, et al., Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 2013; 27: 337-44.
7. Aozasa N, Asano Y, Akamata K, et al., Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 2013; 27: 37-42.
8. Kjeldsen L, Johnsen AH, Sengeløv H, et al., Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268: 10425-32.
9. Kehrer JP,. Lipocalin-2: pro- or anti-apoptotic? Cell Biol Toxicol 2010; 26: 83-9.
10. Flo TH, Smith KD, Sato S, et al., Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432: 917-21.
11. Zhang J, Wu Y, Zhang Y, et al., The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol 2008; 22: 1416-26.
12. Wang Y, Lam KS, Kraegen EW, et al., Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007; 53: 34-41.
13. Borkham-Kamphorst E, Drews F, Weiskirchen R,. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation. Liver Int 2011; 31: 656-65.
14. McReynolds MR, Taylor-Garcia KM, Greer KA, et al., Renal medullary gene expression in aquaporin-1 null mice. Am J Physiol Renal Physiol 2005; 288: F315-21.
15. Ko GJ, Grigoryev DN, Linfert D, et al., Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI-to-CKD transition. Am J Physiol Renal Physiol 2010; 298: F1472-83.
16. Viau A, El Karoui K, Laouari D, et al., Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010; 120: 4065-76.
17. Milner KL, van der Poorten D, Xu A, et al., Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1926-34.
18. Kim JW, Lee SH, Jeong SH, et al., Increased urinary lipocalin-2 reflects matrix metalloproteinase-9 activity in chronic hepatitis C with hepatic fibrosis. Tohoku J Exp Med 2010; 222: 319-27.
19. Mishra J, Ma Q, Prada A, et al., Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534-43.
20. Devarajan P,. Emerging biomarkers of acute kidney injury. Contrib Nephrol 2007; 156: 203-12.
21. Haase M, Bellomo R, Devarajan P, et al., Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1012-24.
22. Haase-Fielitz A, Bellomo R, Devarajan P, et al., The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol Dial Transplant 2009; 24: 3349-54.
23. Leng X, Ding T, Lin H, et al., Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 2009; 69: 8579-84.
24. Lin CW, Tseng SW, Yang SF, et al., Role of lipocalin 2 and its complex with matrix metalloproteinase-9 in oral cancer. Oral Dis 2012; 18: 734-40.
25. Hanai J, Mammoto T, Seth P, et al., Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem 2005; 280: 13641-7.
26. Yang J, Bielenberg DR, Rodig SJ, et al., Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 2009; 106: 3913-18.
27. Venkatesha S, Hanai J, Seth P, et al., Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells. Mol Cancer Res 2006; 4: 821-9.
28. Fernández CA, Yan L, Louis G, et al., The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005; 11: 5390-5.
29. Bauer M, Eickhoff JC, Gould MN, et al., Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008; 108: 389-97.
30. Li EM, Xu LY, Cai WJ, et al., Functions of neutrophil gelatinase-associated lipocalin in the esophageal carcinoma cell line SHEEC. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003; 35: 247-54.
31. Leng X, Lin H, Ding T, et al., Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 2008; 27: 6110-19.
32. LeRoy E, Black C, Fleischmajer R, et al., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
33. van den Hoogen F, Khanna D, Fransen J, et al., 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
34. van den Hoogen F, Khanna D, Fransen J, et al., 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-55.
35. Noda S, Asano Y, Aozasa N, et al., Clinical significance of serum soluble Tie1 levels in patients with systemic sclerosis. Arch Dermatol Res 2013; 305: 325-31.
36. Asano Y, Czuwara J, Trojanowska M,. Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007; 282: 34672-83.
37. Yoshizaki A, Iwata Y, Komura K, et al., CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-63.
38. Ichimura Y, Asano Y, Akamata K, et al., Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. Arch Dermatol Res 2014; 306: 331-8.
39. Steen VD, Medsger TA Jr,. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
40. Feghali-Bostwick C, Medsger TA, Wright TM,. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 1956-63.
41. Wang Y, Fan PS, Kahaleh B,. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-9.
42. Asano Y, Stawski L, Hant F, et al., Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-98.
43. Yan L, Borregaard N, Kjeldsen L, et al., The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276: 37258-65.
44. Lafyatis R, York M,. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009; 21: 617-22.
45. Matsushita T, Hasegawa M, Hamaguchi Y, et al., Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33: 275-84.
46. Baraut J, Michel L, Verrecchia F, et al., Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010; 10: 65-73.
47. Grigoryev DN, Mathai SC, Fisher MR, et al., Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res 2008; 151: 197-207.
48. Giannelli G, Iannone F, Marinosci F, et al., The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin 2005; 21: 327-32.
49. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al., Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004; 94: 1101-8.
50. Roy R, Louis G, Loughlin KR, et al., Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008; 14: 6610-17.
51. Song E, Fan P, Huang B, et al., Deamidated lipocalin-2 induces endothelial dysfunction and hypertension in dietary obese mice. J Am Heart Assoc 2014; 3: e000837.
52. Chung TW, Choi HJ, Kim CH, et al., Lipocalin-2 elicited by advanced glycation end-products promotes the migration of vascular smooth muscle cells. Biochim Biophys Acta 2013; 1833: 3386-95.
53. Liu JT, Song E, Xu A, et al., Lipocalin-2 deficiency prevents endothelial dysfunction associated with dietary obesity: role of cytochrome P450 2C inhibition. Br J Pharmacol 2012; 165: 520-31.